アブストラクト
| Title | 抗真菌薬の予防投与 |
|---|---|
| Subtitle | 特集 抗真菌薬選択がよくわかる 表在性皮膚真菌症・深在性真菌症の薬物治療 深在性真菌症の薬物治療 |
| Authors | 冲中敬二 |
| Authors (kana) | |
| Organization | 国立がん研究センター東病院感染症科 |
| Journal | 月刊薬事 |
| Volume | 65 |
| Number | 8 |
| Page | 1607-1611 |
| Year/Month | 2023 / 6 |
| Article | 報告 |
| Publisher | じほう |
| Abstract | 「Key Points」●深在性真菌症は早期診断が難しく, 死亡率も高いため, リスクが高い場合には予防投与や防護環境下での管理が推奨される. ●侵襲性カンジダ感染症予防 - 急性骨髄性白血病や骨髄異形成症候群の寛解導入療法や同種造血幹細胞移植のような長期の好中球減少が予測される場合には予防投与が推奨される. - 集中治療室(ICU)における好中球減少のない重症患者への一律の予防投与は推奨されていない. ●侵襲性アスペルギルス感染症予防 - 基本は防護環境下での管理となるが, リスクが高い場合には予防投与も考慮する. |
| Practice | 薬学 |
| Keywords |
- 全文ダウンロード： 従量制、基本料金制の方共に803円(税込) です。
参考文献
- 1) Siegel JD, et al: 2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings. Am J Infect Control, 35(Suppl 2):S65-164, 2007
- 2) Pizzo PA, et al: Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. The American journal of medicine, 72:101-111, 1982
- 3) Empiric antifungal therapy in febrile granulocytopenic patients. EORTC International Antimicrobial Therapy Cooperative Group. The American journal of medicine, 86:668-672, 1989
- 4) Kanda Y, et al: Prophylactic action of oral fluconazole against fungal infection in neutropenic patients. A meta-analysis of 16 randomized, controlled trials. Cancer, 89:1611-1625, 2000
- 5) 日本臨床腫瘍学会・編:発熱性好中球減少症(FN)診療ガイドライン 改訂第2版 がん薬物療法時の感染対策.南江堂,p77, 2017
残りの13件を表示する
- 6) Taplitz RA, et al: Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression: ASCO and IDSA Clinical Practice Guideline Update. Journal of clinical oncology: official journal of the American Society of Clinical Oncology, 36:3043-3054, 2018
- 7) Pagano L, et al: Changes in the incidence of candidemia and related mortality in patients with hematologic malignancies in the last ten years. A SEIFEM 2015-B report. Haematologica, 102:e407-e410, 2017
- 8) Pappas PG, et al: Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 62:e1-50, 2016
- 9) Ostrosky-Zeichner L, et al: MSG-01:A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America, 58:1219-1226, 2014
- 10) Martin-Loeches I, et al: ESICM/ESCMID task force on practical management of invasive candidiasis in critically ill patients. Intensive Care Med, 45:789-805, 2019
- 11) 日本医真菌学会侵襲性カンジダ症に対するマネジメントのための臨床実践ガイドライン作成委員会・編:侵襲性カンジダ症に対するマネジメントのための臨床実践ガイドライン=Clinical Practice Guidelines for the Management of Invasive Candidiasis by the Japanese Society for Medical Mycology. 日本医真菌学会, 2021
- 12) Leon C, et al: Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: a prospective multicenter study. Critical care medicine, 37:1624-1633, 2009
- 13) Playford EG, et al: Problematic Dichotomization of Risk for Intensive Care Unit (ICU)-Acquired Invasive Candidiasis: Results Using a Risk-Predictive Model to Categorize 3 Levels of Risk From a Multicenter Prospective Cohort of Australian ICU Patients. Clin Infect Dis, 63:1463-1469, 2016
- 14) Stanzani M, et al: Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies. The Journal of infection, 78:484-490, 2019
- 15) Portugal RD, et al: Index to predict invasive mold infection in high-risk neutropenic patients based on the area over the neutrophil curve. J Clin Oncol, 27:3849-3854, 2009
- 16) Maertens J, et al; Infectious Diseases Group and the Acute Leukemia Group of the European Organization for Research and Treatment of Cancer: Empiric vs Preemptive Antifungal Strategy in High-Risk Neutropenic Patients on Fluconazole Prophylaxis: A Randomized Trial of the European Organization for Research and Treatment of Cancer. Clin Infect Dis, 76:674-682, 2023
- 17) Maertens JA, et al: European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother, 73:3221-3230, 2018
- 18) NCCN.org. Prevention and Treatment of Cancer-Related Infections 2023 [Version 3. 2022 (https://www.nccn.org/professionals/physician_gls/pdf/infections.pdf.)
